Key Highlights:
- Boston Scientific (BSX, Financial) achieves 22% operational sales growth in Q1 2025.
- Updated full-year growth guidance now targets 12%-14% organic growth.
- Wall Street analysts' average price target suggests a potential 16.10% upside.
Boston Scientific (BSX) delivered impressive Q1 2025 financial results, revealing a noteworthy 22% boost in operational sales and an 18% increase in organic growth, surpassing prior projections. The company's adjusted EPS soared to $0.75. Consequently, Boston Scientific revised its full-year organic growth guidance to a substantial 12%-14%, setting the stage for an expected 2025 EPS range between $2.87 and $2.94.
Wall Street Analysts Forecast
According to projections from 30 Wall Street analysts, the average price target for Boston Scientific Corp (BSX, Financial) stands at $116.34. Estimates vary, with a high of $130.00 and a low at $84.11, indicating a promising upside of 16.10% from the current trading price of $100.20. For an in-depth analysis, visit the Boston Scientific Corp (BSX) Forecast page.
The consensus recommendation from 34 brokerage firms places Boston Scientific Corp (BSX, Financial) at an average rating of 1.8, which aligns with an "Outperform" status. This rating operates on a scale from 1 to 5, where 1 equates to a Strong Buy, and 5 signifies a Sell.
Utilizing GuruFocus estimates, the projected GF Value for Boston Scientific Corp (BSX, Financial) over the next year is $76.97. This estimate suggests a potential downside of 23.18% from the current price point of $100.20. The GF Value represents GuruFocus’ fair value estimate for the stock, calculated using historical trading multiples, past business growth, and forecasts of future performance. Explore more on the Boston Scientific Corp (BSX) Summary page.
